Additionally, changes in ER’s genomic binding and widespread alterations to chromatin accessibility, accompanied by binding of other transcription-regulating factors such as CTCF, FOXA1 and OCT1, can explain an additional 20–30% of transcriptional changes observed in ER mutant breast cancer cells. This evidence concerns the gene ESR1 and breast cancer.